Organisation paid for research Program year 2025 Source: CMS Open Payments

MD Medical Research

Neither a doctor nor a teaching hospital

Research payments

$4,417,044

854 payments

Through program year 2025, MD Medical Research is reported as receiving $4,417,044 in research payments, across 854 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,238,778 56
2024 Research $831,131 25
2023 Research $778,671 70
2022 Research $792,895 170
2021 Research $532,425 384
2020 Research $89,071 110
2019 Research $154,074 39

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,278,467 27 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $696,560 33 payments
  3. Genentech, Inc. $505,003 36 payments
  4. LivaNova USA, Inc. $503,690 24 payments
  5. Novo Nordisk AS $452,309 703 payments
  6. Amgen Inc. $346,799 2 payments
  7. AstraZeneca Pharmaceuticals LP $216,147 4 payments
  8. Vertex Pharmaceuticals Incorporated $201,556 2 payments
  9. Mylan Specialty L.P. $136,441 10 payments
  10. AstraZeneca UK Limited $27,578 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Faricimab for Under Represented Patients With Dme $505,003 36 payments
  2. ANTHEM HFrEF $503,690 24 payments
  3. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity Or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-2) $427,467 4 payments
  4. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $425,642 10 payments
  5. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $375,601 32 payments
  6. Obesity Long term safety in patients with CV risk $320,959 1 payment
  7. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $314,448 1 payment
  8. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $201,556 2 payments
  9. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $182,761 3 payments
  10. Ex9536-4388 $138,514 163 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record